# A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors

> **NCT04908046** · PHASE1 · COMPLETED · sponsor: **Hutchmed** · enrollment: 47 (actual)

## Conditions studied

- Advanced Malignant Solid Tumors

## Interventions

- **DRUG:** HMPL-295S1 with dose escalation stage of 5mg up to 200mg, then expansion stage with recommended dose of therapeutic cycle of 28 days .

## Key facts

- **NCT ID:** NCT04908046
- **Lead sponsor:** Hutchmed
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-27
- **Primary completion:** 2024-01-29
- **Final completion:** 2024-02-23
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04908046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04908046, "A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04908046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*